Related references
Note: Only part of the references are listed.Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography
Sarah Walz et al.
ELECTROPHORESIS (2015)
A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma
Muzaffar Iqbal et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2015)
Population Pharmacokinetics of Pomalidomide
Yan Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Identification and characterization of related substances in pomalidomide by hyphenated LC-MS techniques
Ping Lu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2015)
Chiral selectors in CE: Recent developments and applications (2012-mid 2014)
Ioannis J. Stavrou et al.
ELECTROPHORESIS (2015)
A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses
Shandiz Shahbazi et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)
Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue
Yao Jiang et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)
Modeling and Simulation to Probe the Pharmacokinetic Disposition of Pomalidomide R- and S-Enantiomers
Yan Li et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
Matthew Hoffmann et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
CTP-221, a deuterated S-enantiomer of lenalidomide, is greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide.
Vinita Uttamsingh et al.
CANCER RESEARCH (2013)
Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Shuang Zhou et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease
James H. Kim et al.
TOXICOLOGICAL SCIENCES (2011)
Chemometric experimental design based optimization techniques in capillary electrophoresis: a critical review of modern applications
Grady Hanrahan et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2008)
Thalidomide analogues as anticancer drugs
Jeanny B. Aragon-Ching et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2007)
The thalidomide saga
Magda Melchert et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Chiral inversion of the second generation IMiD™ CC-4047 (ACTIMID™) in human plasma and phosphate-buffered saline
SK Teo et al.
CHIRALITY (2003)
Intravenous formulations of the enantiomers of thalidomide:: Pharmacokinetic and initial pharmacodynamic characterization in man
T Eriksson et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2000)
Share Paper
